細胞解離の市場規模、シェア、動向分析レポートタイプ別（細胞剥離、組織解離）、製品別（酵素解離）、最終用途別、地域別、セグメント予測、2023年～2030年

細胞解離の市場成長と動向

Grand View Research, Inc.の新しいレポートによると、世界の細胞解離市場規模は2030年までに8億6330万米ドルに達し、全体の収益の13.55%のCAGRを記録すると予測されています。

慢性疾患や感染症の有病率の上昇と、細胞ベースの治療薬への注目度の高まりが、市場の成長を後押ししています。また、細胞ベースの研究に対する資金提供の増加や、自動化された機器の使用の増加が、業界を牽引する主な要因となっています。研究用モデルシステムとしての患者由来細胞の用途が拡大する中、高品質の細胞材料の必要性が常に発展しています。組織から個々の細胞を抽出する能力は、現在、細胞ベースの診断技術のボトルネックとなっており、組織工学、新たな診断法、がん研究、個別化医療アプローチの分野では依然として不可欠です。

主な課題は、細胞の品質と収量、純度と完全性、再現性とスループットです。これらの限界を克服するために、Institut fur Politikwissenschaftの研究者は、標準的な50ml遠心分離機チューブに組み込まれた逆回転する研削歯列をベースにした機械的組織分解システムを開発しています。COVID-19のパンデミックは、市場の成長にプラスの影響を与えました。細胞解離と組織解離は、主に間葉系間質細胞（MSC）を用いた細胞ベースの治療法を支援するために使用されます。その結果、COVID-19の流行により、これらの酵素の使用量が増加し、市場成長が促進されました。近年、幹細胞治療は先進的で有望な科学研究テーマとなっています。

治療法の開発により、大きなチャンスがもたらされています。幹細胞は、医学の最も重要な側面のひとつになる可能性を大いに秘めています。幹細胞は回復療法の開発に大きな役割を果たすだけでなく、その研究は、人間の成長過程で起こる複雑な出来事に関する新たな情報を明らかにするものでもあります。さらに、幹細胞の生物学を研究するための基礎研究において細胞培養が広く用いられているだけでなく、培養幹細胞の治療への応用が期待されていることから、幹細胞培養の改良に関心が高まっています。解離は、創薬、開発、細胞治療など、さまざまな研究や治療への応用において重要な役割を担っています。

さらに、臨床試験の増加、FDAの承認、大手企業による協業などの戦略的取り組みが、業界の成長を後押ししています。例えば、2021年10月、ドイツに本社を置き、革新的な幹細胞治療薬の臨床開発に注力するバイオ医薬品企業であるRHEACELL社は、細胞治療製品AMESANARについてドイツ医薬品法に基づく国内承認を取得しました。2023年2月、IASO Biotherapeutics社は、再発/難治性多発性骨髄腫に対するIND BCMA CAR-T CT103Aについて、USFDAから再生医療先進医療指定とファストトラック指定を受けた。原材料に関する厳しい規制や動物由来製品に関する倫理的な問題は、業界の成長を一定程度妨げる可能性があります。

細胞治療製品の製造に関するガイドラインは、まだ進行中です。しかし、関連する文献はUSP1046であり、製造工程で使用される原材料の適格性を指定するものです。したがって、原材料の一貫性、原産地、不純物のリスク、GMPガイドラインの下で製造された原材料かどうかなどの懸念事項を考慮することは、承認にとって意義があります。しかし、動物由来でない、GMPグレードの酵素への関心が高まっており、予測期間中の業界の成長を促進することになるでしょう。北米は、慢性疾患の発症率の高さ、細胞治療に対する政府による投資資金の増加、研究所や臨床研究のための高品質なインフラの存在により、2022年に世界の業界を支配しました。

細胞解離市場レポートハイライト

• 酵素解離製品セグメントは、製薬＆バイオテクノロジー企業における酵素解離製品の要件と重要性の増加により、2022年に最も高いシェアを占め、その結果、導入が促進され、セグメントの成長が期待されます。
• 組織解離タイプは、研究開発活動の活発化と慢性疾患の高い有病率により、2022年に最大の収益シェアを占めました。
• 細胞ベースの治療薬の臨床試験の増加、FDAの承認、細胞・遺伝子治療に関する研究により、バイオ医薬品・製薬会社のエンドユーザー部門が2022年に業界をリードしました。
• アジア太平洋地域は、予測期間中に最も速い成長率を記録すると予想されます。
• これは、新規治療薬に対する需要の高まりと急速なインフラ整備に起因しています。

目次

第1章 調査手法

• 市場セグメンテーションと範囲
• 調査手法
• 情報調達
  • 購入したデータベース
  • GVRの内部データベース
  • 二次情報
  • 1次調査
  • 1次調査の詳細
• 情報またはデータ分析
  • データ分析モデル
• 市場の策定と検証
• モデルの詳細
  • コモディティフロー分析
    • アプローチ1：コモディティフローアプローチ
    • アプローチ2：ボトムアップアプローチを使用した国別の市場推定
• 世界市場：CAGR計算
• 調査の仮定
• 二次情報一覧
• 一次情報のリスト
• 目的
• 略語一覧

第2章 市場の定義

第3章 エグゼクティブサマリー

• 市場概要

第4章 世界の細胞解離市場の変数、動向、および範囲

• 細胞解離市場系統の見通し
  • 親市場の見通し
• 浸透と成長の見通しのマッピング
• 市場促進要因分析
  • 細胞ベースの治療法の開発への関心の高まり
  • 細胞ベースの調査に対する資金の増加
  • 細胞解離装置の技術的進歩
• 市場抑制要因分析
  • 厳しい規制
• 市場機会分析
  • 幹細胞調査への注目の高まり
• ポーターのファイブフォース分析
• 細胞解離市場： COVID-19影響分析

第5章 細胞解離市場-セグメント分析、製品別、2018年から2030年（百万米ドル）

• 世界の細胞解離市場：製品変動分析
• 酵素的解離
  • トリプシン
  • コラゲナーゼ
  • エラスターゼ
  • パパイン
  • ヒアルロニダーゼ
  • DNアーゼ
  • その他
• 非酵素的解離
• 機器とアクセサリー

第6章 細胞解離市場-セグメント分析、タイプ別、2018年から2030年（百万米ドル）

• 世界の細胞解離市場：型変動分析
• 組織解離
• 細胞剥離

第7章 細胞解離市場-セグメント分析、最終用途別、2018年から2030年（百万米ドル）

• 細胞解離市場：エンドユーザーの変動分析
• 製薬およびバイオテクノロジー企業
• 調査・学術機関

第8章 細胞解離市場：-セグメント分析、地域別、2018年から2030年（百万米ドル）

• 細胞解離市場：地域変動分析
• 北米
  • SWOT分析
  • 米国
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
  • カナダ
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
• 欧州
  • SWOT分析
  • ドイツ
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
  • 英国
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
  • フランス
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
  • イタリア
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
  • スペイン
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
  • デンマーク
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
  • スウェーデン
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
  • ノルウェー
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
• アジア太平洋地域
  • SWOT分析
  • 日本
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
  • 中国
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
  • インド
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
  • 韓国
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
  • オーストラリア
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
  • タイ
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
• ラテンアメリカ
  • SWOT分析
  • ブラジル
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
  • メキシコ
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
  • アルゼンチン
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
• MEA
  • SWOT分析
  • 南アフリカ
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
  • サウジアラビア
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
  • アラブ首長国連邦
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み
  • クウェート
    • 主要な国のダイナミクス
    • 対象疾患の有病率
    • 競合シナリオ
    • 規制の枠組み

第9章 競合情勢

• 企業の分類
• 企業の市場ポジショニング
• 企業の市場シェア分析、2022 年
• 企業のヒートマップ分析
• 戦略マッピング
• 企業プロファイル・一覧
  • Thermo Fisher Scientific Inc.
    • Overview
    • Financial performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • Product benchmarking
    • Strategic initiatives
  • Danaher Corporation
    • Overview
    • Financial performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • Product benchmarking
    • Strategic initiatives
  • STEMCELL Technologies
    • Overview
    • Financial performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • Product benchmarking
    • Strategic initiatives
  • Merck KGaA
    • Overview
    • Financial performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • Product benchmarking
    • Strategic initiatives
  • BD
    • Overview
    • Financial performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • Product benchmarking
    • Strategic initiatives
  • Sartorius AG
    • Overview
    • Financial performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • Product benchmarking
    • Strategic initiatives
  • Miltenyi Biotec
    • Overview
    • Financial performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • Product benchmarking
    • Strategic initiatives
  • PAN-Biotech
    • Overview
    • Financial performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • Product benchmarking
    • Strategic initiatives
  • HiMedia Laboratories
    • Overview
    • Financial performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • Product benchmarking
    • Strategic initiatives
  • F. Hoffmann-La Roche Ltd
    • Overview
    • Financial performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • Product benchmarking
    • Strategic initiatives
  • S2 Genomics, Inc.
    • Overview
    • Financial performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • Product benchmarking
    • Strategic initiatives

List of Tables

• Table 1. List of secondary sources
• Table 2. List of abbreviations
• Table 3. Global cell dissociation market, by product, 2018 - 2030 (USD Million)
• Table 4. Global cell dissociation market, by type, 2018 - 2030 (USD Million)
• Table 5. Global cell dissociation market, end-user, 2018 - 2030 (USD Million)
• Table 6. Global cell dissociation market, by region, 2018 - 2030 (USD Million)
• Table 7. North America cell dissociation market, by country, 2018 - 2030 (USD Million)
• Table 8. North America cell dissociation market, by product, 2018 - 2030 (USD Million)
• Table 9. North America cell dissociation market, by type, 2018 - 2030 (USD Million)
• Table 10. North America cell dissociation market, end-user, 2018 - 2030 (USD Million)
• Table 11. U.S. Cell dissociation market, by product, 2018 - 2030 (USD Million)
• Table 12. U.S. Cell dissociation market, by type, 2018 - 2030 (USD Million)
• Table 13. U.S. Cell dissociation market, end-user, 2018 - 2030 (USD Million)
• Table 14. Canada cell dissociation market, by product, 2018 - 2030 (USD Million)
• Table 15. Canada cell dissociation market, by type, 2018 - 2030 (USD Million)
• Table 16. Canada cell dissociation market, end-user, 2018 - 2030 (USD Million)
• Table 17. Europe cell dissociation market, by country, 2018 - 2030 (USD Million)
• Table 18. Europe cell dissociation market, by product, 2018 - 2030 (USD Million)
• Table 19. Europe cell dissociation market, by type, 2018 - 2030 (USD Million)
• Table 20. Europe cell dissociation market, end-user, 2018 - 2030 (USD Million)
• Table 21. U.K. cell dissociation market, by product, 2018 - 2030 (USD Million)
• Table 22. U.K. cell dissociation market, by type, 2018 - 2030 (USD Million)
• Table 23. U.K. cell dissociation market, end-user, 2018 - 2030 (USD Million)
• Table 24. Germany cell dissociation market, by product, 2018 - 2030 (USD Million)
• Table 25. Germany cell dissociation market, by type, 2018 - 2030 (USD Million)
• Table 26. Germany cell dissociation market, end-user, 2018 - 2030 (USD Million)
• Table 27. France cell dissociation market, by product, 2018 - 2030 (USD Million)
• Table 28. France cell dissociation market, by type, 2018 - 2030 (USD Million)
• Table 29. France cell dissociation market, end-user, 2018 - 2030 (USD Million)
• Table 30. Italy cell dissociation market, by product, 2018 - 2030 (USD Million)
• Table 31. Italy cell dissociation market, by type, 2018 - 2030 (USD Million)
• Table 32. Italy cell dissociation market, end-user, 2018 - 2030 (USD Million)
• Table 33. Spain cell dissociation market, by product, 2018 - 2030 (USD Million)
• Table 34. Spain cell dissociation market, by type, 2018 - 2030 (USD Million)
• Table 35. Spain cell dissociation market, end-user, 2018 - 2030 (USD Million)
• Table 36. Denmark cell dissociation market, by product, 2018 - 2030 (USD Million)
• Table 37. Denmark cell dissociation market, by type, 2018 - 2030 (USD Million)
• Table 38. Denmark cell dissociation market, end-user, 2018 - 2030 (USD Million)
• Table 39. Sweden cell dissociation market, by product, 2018 - 2030 (USD Million)
• Table 40. Sweden cell dissociation market, by type, 2018 - 2030 (USD Million)
• Table 41. Sweden cell dissociation market, end-user, 2018 - 2030 (USD Million)
• Table 42. Norway cell dissociation market, by product, 2018 - 2030 (USD Million)
• Table 43. Norway cell dissociation market, by type, 2018 - 2030 (USD Million)
• Table 44. Norway cell dissociation market, end-user, 2018 - 2030 (USD Million)
• Table 45. Asia Pacific cell dissociation market, by country, 2018 - 2030 (USD Million)
• Table 46. Asia Pacific cell dissociation market, by product, 2018 - 2030 (USD Million)
• Table 47. Asia Pacific cell dissociation market, by type, 2018 - 2030 (USD Million)
• Table 48. Asia pacific cell dissociation market, end-user, 2018 - 2030 (USD Million)
• Table 49. China cell dissociation market, by product, 2018 - 2030 (USD Million)
• Table 50. China cell dissociation market, by type, 2018 - 2030 (USD Million)
• Table 51. China cell dissociation market, end-user, 2018 - 2030 (USD Million)
• Table 52. India cell dissociation market, by product, 2018 - 2030 (USD Million)
• Table 53. India cell dissociation market, by type, 2018 - 2030 (USD Million)
• Table 54. India cell dissociation market, end-user, 2018 - 2030 (USD Million)
• Table 55. Japan cell dissociation market, by product, 2018 - 2030 (USD Million)
• Table 56. Japan cell dissociation market, by type, 2018 - 2030 (USD Million)
• Table 57. Japan cell dissociation market, end-user, 2018 - 2030 (USD Million)
• Table 58. Thailand cell dissociation market, by product, 2018 - 2030 (USD Million)
• Table 59. Thailand cell dissociation market, by type, 2018 - 2030 (USD Million)
• Table 60. Thailand cell dissociation market, end-user, 2018 - 2030 (USD Million)
• Table 61. Australia cell dissociation market, by product, 2018 - 2030 (USD Million)
• Table 62. Australia cell dissociation market, by type, 2018 - 2030 (USD Million)
• Table 63. Australia cell dissociation market, end-user, 2018 - 2030 (USD Million)
• Table 64. South Korea cell dissociation market, by product, 2018 - 2030 (USD Million)
• Table 65. South Korea cell dissociation market, by type, 2018 - 2030 (USD Million)
• Table 66. South Korea cell dissociation market, end-user, 2018 - 2030 (USD Million)
• Table 67. Latin America cell dissociation market, by country, 2018 - 2030 (USD Million)
• Table 68. Latin America cell dissociation market, by product, 2018 - 2030 (USD Million)
• Table 69. Latin America cell dissociation market, by type, 2018 - 2030 (USD Million)
• Table 70. Latin America cell dissociation market, end-user, 2018 - 2030 (USD Million)
• Table 71. Brazil cell dissociation market, by product, 2018 - 2030 (USD Million)
• Table 72. Brazil cell dissociation market, by type, 2018 - 2030 (USD Million)
• Table 73. Brazil cell dissociation market, end-user, 2018 - 2030 (USD Million)
• Table 74. Mexico cell dissociation market, by product, 2018 - 2030 (USD Million)
• Table 75. Mexico cell dissociation market, by type, 2018 - 2030 (USD Million)
• Table 76. Mexico cell dissociation market, end-user, 2018 - 2030 (USD Million)
• Table 77. Argentina cell dissociation market, by product, 2018 - 2030 (USD Million)
• Table 78. Argentina cell dissociation market, by type, 2018 - 2030 (USD Million)
• Table 79. Argentina cell dissociation market, end-user, 2018 - 2030 (USD Million)
• Table 80. Middle East & Africa cell dissociation market, by country, 2018 - 2030 (USD Million)
• Table 81. Middle East & Africa cell dissociation market, by product, 2018 - 2030 (USD Million)
• Table 82. Middle East & Africa cell dissociation market, by type, 2018 - 2030 (USD Million)
• Table 83. Middle East & Africa cell dissociation market, end-user, 2018 - 2030 (USD Million)
• Table 84. South Africa cell dissociation market, by product, 2018 - 2030 (USD Million)
• Table 85. South Africa cell dissociation market, by type, 2018 - 2030 (USD Million)
• Table 86. South Africa cell dissociation market, end-user, 2018 - 2030 (USD Million)
• Table 87. Saudi Arabia cell dissociation market, by product, 2018 - 2030 (USD Million)
• Table 88. Saudi Arabia cell dissociation market, by type, 2018 - 2030 (USD Million)
• Table 89. Saudi Arabia cell dissociation market, end-user, 2018 - 2030 (USD Million)
• Table 90. UAE cell dissociation market, by product, 2018 - 2030 (USD Million)
• Table 91. UAE cell dissociation market, by type, 2018 - 2030 (USD Million)
• Table 92. UAE cell dissociation market, end-user, 2018 - 2030 (USD Million)
• Table 93. Kuwait cell dissociation market, by product, 2018 - 2030 (USD Million)
• Table 94. Kuwait cell dissociation market, by type, 2018 - 2030 (USD Million)
• Table 95. Kuwait cell dissociation market, end-user, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Information procurement
• Fig. 3 Primary research pattern
• Fig. 4 Market research approaches
• Fig. 5 Value chain-based sizing & forecasting
• Fig. 6 Market formulation & validation
• Fig. 7 Cell dissociation, market segmentation
• Fig. 8 Market snapshot, 2021
• Fig. 9 Market trends & outlook
• Fig. 10 Market driver relevance analysis (current & future impact)
• Fig. 11 Market restraint relevance analysis (current & future impact)
• Fig. 12 Market challenge relevance analysis (current & future impact)
• Fig. 13 SWOT analysis, by factor (political & legal, economic and technological)
• Fig. 14 Porter's five forces analysis
• Fig. 15 Market penetration vs growth prospect mapping, 2021
• Fig. 16 Global cell dissociation market: product movement analysis
• Fig. 17 Global cell dissociation market, for enzymatic dissociation, 2018 - 2030 (USD Million)
• Fig. 18 Global cell dissociation market, for trypsin, 2018 - 2030 (USD Million)
• Fig. 19 Global cell dissociation market, for collagenase, 2018 - 2030 (USD Million)
• Fig. 20 Global cell dissociation market, for elastase, 2018 - 2030 (USD Million)
• Fig. 21 Global cell dissociation market, for papain, 2018 - 2030 (USD Million)
• Fig. 22 Global cell dissociation market, for hyaluronidase, 2018 - 2030 (USD Million)
• Fig. 23 Global cell dissociation market, for DNase, 2018 - 2030 (USD Million)
• Fig. 24 Global cell dissociation market, for others, 2018 - 2030 (USD Million)
• Fig. 25 Global cell dissociation market, for non-enzymatic dissociation, 2018 - 2030 (USD Million)
• Fig. 26 Global cell dissociation market, for instruments & accessories, 2018 - 2030 (USD Million)
• Fig. 27 Global cell dissociation market: type movement analysis
• Fig. 28 Global cell dissociation market, for tissue dissociation, 2018 - 2030 (USD Million)
• Fig. 29 Global cell dissociation market, for cell detachment, 2018 - 2030 (USD Million)
• Fig. 30 Global cell dissociation market: end-user movement analysis
• Fig. 31 Global cell dissociation market, for pharmaceutical and biotechnology companies, 2018 - 2030 (USD Million)
• Fig. 32 Global cell dissociation market, for research and academics institutes, 2018 - 2030 (USD Million)
• Fig. 33 Regional marketplace: key takeaways
• Fig. 34 Regional outlook, 2022 & 2030
• Fig. 35 Global flow cytometry market: region movement analysis
• Fig. 36 North America cell dissociation market, 2018 - 2030 (USD Million)
• Fig. 37 U.S. Cell dissociation market, 2018 - 2030 (USD Million)
• Fig. 38 Canada cell dissociation market, 2018 - 2030 (USD Million)
• Fig. 39 Europe cell dissociation market, 2018 - 2030 (USD Million)
• Fig. 40 U.K. cell dissociation market, 2018 - 2030 (USD Million)
• Fig. 41 Germany cell dissociation market, 2018 - 2030 (USD Million)
• Fig. 42 France cell dissociation market, 2018 - 2030 (USD Million)
• Fig. 43 Italy cell dissociation market, 2018 - 2030 (USD Million)
• Fig. 44 Spain cell dissociation market, 2018 - 2030 (USD Million)
• Fig. 45 Denmark cell dissociation market, 2018 - 2030 (USD Million)
• Fig. 46 Sweden cell dissociation market, 2018 - 2030 (USD Million)
• Fig. 47 Norway cell dissociation market, 2018 - 2030 (USD Million)
• Fig. 48 Asia pacific cell dissociation market, 2018 - 2030 (USD Million)
• Fig. 49 China cell dissociation market, 2018 - 2030 (USD Million)
• Fig. 50 India cell dissociation market, 2018 - 2030 (USD Million)
• Fig. 51 Japan cell dissociation market, 2018 - 2030 (USD Million)
• Fig. 52 Thailand cell dissociation market, 2018 - 2030 (USD Million)
• Fig. 53 Australia cell dissociation market, 2018 - 2030 (USD Million)
• Fig. 54 South Korea cell dissociation market, 2018 - 2030 (USD Million)
• Fig. 55 Latin America cell dissociation market, 2018 - 2030 (USD Million)
• Fig. 56 Brazil cell dissociation market, 2018 - 2030 (USD Million)
• Fig. 57 Mexico cell dissociation market, 2018 - 2030 (USD Million)
• Fig. 58 Argentina cell dissociation market, 2018 - 2030 (USD Million)
• Fig. 59 Middle East and Africa cell dissociation market, 2018 - 2030 (USD Million)
• Fig. 60 South Africa cell dissociation market, 2018 - 2030 (USD Million)
• Fig. 61 Saudi Arabia cell dissociation market, 2018 - 2030 (USD Million)
• Fig. 62 UAE cell dissociation market, 2018 - 2030 (USD Million)
• Fig. 63 Kuwait cell dissociation market, 2018 - 2030 (USD Million)

Cell Dissociation Market Growth & Trends:

The global cell dissociation market size is expected to reach USD 863.3 million by 2030, registering a CAGR of 13.55% of the overall revenue, according to a new report by Grand View Research, Inc. The rising prevalence of chronic and infectious diseases, coupled with the increasing focus on cell-based therapeutics, is boosting market growth. In addition, growing funding for cell-based research and increasing use of automated instruments are the key factors driving the industry. With the growing applications of patient-derived cells as a model system for research, the necessity for high-quality cell material is constantly developing. The capability to extract individual cells from tissues is presently a bottleneck for cell-based diagnostic technologies and remains vital in the areas of tissue engineering, emerging diagnostic methods, cancer research, and personalized medicine approaches.

Key challenges comprise the quality and yield or the purity and integrity of cells as well as reproducibility and throughput. To overcome these limitations, researchers from Institut fur Politikwissenschaft are developing a mechanical tissue dissociation system based on counter-rotating rows of grinding teeth integrated into a standard 50 ml centrifuge tube. The COVID-19 pandemic influenced market growth positively. Cell dissociation and tissue dissociation are used to aid cell-based therapies, primarily using Mesenchymal Stromal Cells (MSCs). As a result, the usage of these enzymes increased due to the COVID-19 pandemic, which augmented market growth. In current years, stem cell therapy has become an advanced and promising scientific research topic.

The development of treatment methods has induced great opportunities. Stem cells have considerable potential to become one of the most significant aspects of medicine. In addition to the fact that they play a huge role in developing restorative therapy, their study also divulges additional information about the complex events that happen during human development. Moreover, there is a growing interest in improving stem cell culture, not only because cell culture is extensively used in basic research for studying stem cell biology but also due to the potential therapeutic applications of cultured stem cells. Dissociation plays an important role in various research and therapeutic applications, including drug discovery, development, and cell therapy.

Furthermore, increasing clinical trials, FDA approvals, and strategic initiatives, such as collaborations by major players, are boosting industry growth. For instance, in October 2021, RHEACELL, a biopharmaceutical company headquartered in Germany, focused on the clinical development of innovative stem cell therapeutics, received national approval under the German Medicinal Products Act for its cell therapy product AMESANAR. In February 2023, IASO Biotherapeutics received Regenerative Medicine Advanced Therapy designation and Fast Track designation from USFDA for its IND BCMA CAR-T CT103A for relapsed/refractory multiple myeloma. Stringent regulations for raw materials and ethical issues concerning animal-derived products might hamper the industry's growth to a certain extent.

The guidelines for the manufacturing of cell therapy products are still progressing. Still, the relevant reference is the USP 1046, which designates the significance of qualifying raw materials used in the manufacturing process. Thus, considering the concerns, such as raw material consistency, origin, risk of impurity, and whether the raw material was manufactured under the GMP guidelines, is significant for approval. However, there is a growing interest in Animal-origin free and GMP-grade enzymes, which will drive the industry growth during the forecast period. North America dominated the global industry in 2022 due to the high incidence of chronic diseases, the rise in investment funding by the government for cell therapy, and the presence of high-quality infrastructure for laboratory and clinical research.

Cell Dissociation Market Report Highlights:

• The enzymatic dissociation product segment accounted for the highest share in 2022 due to increased requirements and the importance of enzymatic dissociation products for pharmaceutical & biotechnology companies, which, in turn, is likely to boost the adoption and anticipate the segment growth

• The tissue dissociation type segment held the largest revenue share in 2022 owing to the increased R&D activities and high prevalence of chronic disorders

• The biopharmaceutical & pharmaceutical companies end-user segment led the industry in 2022 owing to growth in clinical trials of cell-based therapeutics, FDA approvals, and research on cell & gene therapy

• The Asia Pacific region is expected to register the fastest growth rate during the forecast period

• This is owing to the rising demand for novel therapeutics and rapid infrastructural development

Table of Contents

Chapter 1 Research Methodology

• 1.1 Market Segmentation & Scope
  • 1.1.1 Estimates And Forecast Timeline
• 1.2 Research Methodology
• 1.3 Information Procurement
  • 1.3.1 Purchased Database
  • 1.3.2 GVR's Internal Database
  • 1.3.3 Secondary Sources
  • 1.3.4 Primary Research
  • 1.3.5 Details Of Primary Research
• 1.4 Information Or Data Analysis
  • 1.4.1 Data Analysis Models
• 1.5 Market Formulation & Validation
• 1.6 Model Details
  • 1.6.1 Commodity Flow Analysis
    • 1.6.1.1 Approach 1: Commodity flow approach
    • 1.6.1.2 Approach 2: Country-wise market estimation using bottom-up approach
• 1.7 Global Market: CAGR Calculation
• 1.8 Research Assumptions
• 1.9 List of Secondary Sources
• 1.10 List of Primary Sources
• 1.11 Objectives
  • 1.11.1 Objective 1:
  • 1.11.2 Objective 2:
• 1.12 List of Abbreviations

Chapter 2 Market Definitions

Chapter 3 Executive Summary

• 3.1 Market Summary

Chapter 4 Global Cell Dissociation Market Variables, Trends, & Scope

• 4.1 Cell Dissociation Market Lineage Outlook
  • 4.1.1 Parent Market Outlook
• 4.2 Penetration And Growth Prospect Mapping
• 4.3 Market Driver Analysis
  • 4.3.1 Rising Focus On The Development Of Cell-Based Therapeutics
  • 4.3.2 Growing Funding For Cell-Based Research
  • 4.3.3 Technological Advancements In Cell Dissociations Instruments
• 4.4 Market Restraint Analysis
  • 4.4.1 Stringent Regulations
• 4.5 Market Opportunity Analysis
  • 4.5.1 Growing Emphasis On Stem Cell Research
• 4.6 Porter's Five Forces Analysis
• 4.7 Cell Dissociation Market: COVID-19 Impact Analysis

Chapter 5 Cell Dissociation Market - Segment Analysis, by Product, 2018 - 2030 (USD Million)

• 5.1 Global Cell Dissociation Market: Product Movement Analysis
• 5.2 Enzymatic Dissociation
  • 5.2.1 Enzymatic Dissociation market estimates and forecast, 2018-2030, USD million
  • 5.2.2 Trypsin
    • 5.2.2.1 Trypsin market estimates and forecast, 2018-2030, USD million
  • 5.2.3 Collagenase
    • 5.2.3.1 Collagenase market estimates and forecast, 2018-2030, USD million
  • 5.2.4 Elastase
    • 5.2.4.1 Elastase market estimates and forecast, 2018-2030, USD million
  • 5.2.5 Papain
    • 5.2.5.1 Papain market estimates and forecast, 2018-2030, USD million
  • 5.2.6 Hyaluronidase
    • 5.2.6.1 Hyaluronidase market estimates and forecast, 2018-2030, USD million
  • 5.2.7 DNase
    • 5.2.7.1 DNase market estimates and forecast, 2018-2030, USD million
  • 5.2.8 Others
    • 5.2.8.1 Others market estimates and forecast, 2018-2030, USD million
• 5.3 Non-Enzymatic Dissociation
  • 5.3.1 Non-Enzymatic dissociation market estimates and forecast, 2018-2030, USD million
• 5.4 Instruments & Accessories
  • 5.4.1 Instruments & accessories market estimates and forecast, 2018-2030, USD million

Chapter 6 Cell Dissociation Market - Segment Analysis, by Type, 2018 - 2030 (USD Million)

• 6.1 Global Cell Dissociation Market: Type Movement Analysis
• 6.2 Tissue Dissociation
  • 6.2.1 Tissue dissociation market estimates and forecast, 2018-2030, USD million
• 6.3 Cell Detachment
  • 6.3.1 Cell detachment market estimates and forecast, 2018-2030, USD million

Chapter 7 Cell Dissociation Market- Segment Analysis, by End-user, 2018 - 2030 (USD Million)

• 7.1 Cell Dissociation Market: End-user Movement Analysis
• 7.2 Pharmaceutical And Biotechnology Companies
  • 7.2.1 Pharmaceutical And Biotechnology Companies market estimates and forecast, 2018-2030, USD million
• 7.3. Research & Academic Institutes
  • 7.3.1 Research & academic institutes market estimates and forecast, 2018-2030, USD million

Chapter 8 Cell Dissociation Market: - Segment Analysis, by Region, 2018 - 2030 (USD Million)

• 8.1 Cell Dissociation Market: Regional Movement Analysis
• 8.2 North America
  • 8.2.1 SWOT analysis
    • 8.2.1.1 North America cell dissociation market, 2018 - 2030 (USD Million)
  • 8.2.2 U.S.
    • 8.2.2.1 Key country dynamics
    • 8.2.2.2 Target disease prevalence
    • 8.2.2.3 Competitive scenario
    • 8.2.2.4 Regulatory framework
    • 8.2.2.5 U.S. cell dissociation market, 2018 - 2030 (USD Million)
  • 8.2.3 Canada
    • 8.2.3.1 Key country dynamics
    • 8.2.3.2 Target disease prevalence
    • 8.2.3.3 Competitive scenario
    • 8.2.3.4 Regulatory framework
    • 8.2.3.5 Canada cell dissociation market, 2018 - 2030 (USD Million)
• 8.3 Europe
  • 8.3.1 SWOT Analysis
    • 8.3.1.1 Europe cell dissociation market, 2018 - 2030 (USD Million)
  • 8.3.2 Germany
    • 8.3.2.1 Key country dynamics
    • 8.3.2.2 Target disease prevalence
    • 8.3.2.3 Competitive scenario
    • 8.3.2.4 Regulatory framework
    • 8.3.2.5 Germany cell dissociation market, 2018 - 2030 (USD Million)
  • 8.3.3 U.K.
    • 8.3.3.1 Key country dynamics
    • 8.3.3.2 Target disease prevalence
    • 8.3.3.3 Competitive scenario
    • 8.3.3.4 Regulatory framework
    • 8.3.3.5 U.K. cell dissociation market, 2018 - 2030 (USD Million)
  • 8.3.4 France
    • 8.3.4.1 Key country dynamics
    • 8.3.4.2 Target disease prevalence
    • 8.3.4.3 Competitive scenario
    • 8.3.4.4 Regulatory framework
    • 8.3.4.5 France cell dissociation market, 2018 - 2030 (USD Million)
  • 8.3.5 Italy
    • 8.3.5.1 Key country dynamics
    • 8.3.5.2 Target disease prevalence
    • 8.3.5.3 Competitive scenario
    • 8.3.5.4 Regulatory framework
    • 8.3.5.5 Italy cell dissociation market, 2018 - 2030 (USD Million)
  • 8.3.6 Spain
    • 8.3.6.1 Key country dynamics
    • 8.3.6.2 Target disease prevalence
    • 8.3.6.3 Competitive scenario
    • 8.3.6.4 Regulatory framework
    • 8.3.6.5 Spain cell dissociation market, 2018 - 2030 (USD Million)
  • 8.3.7 Denmark
    • 8.3.7.1 Key country dynamics
    • 8.3.7.2 Target disease prevalence
    • 8.3.7.3 Competitive scenario
    • 8.3.7.4 Regulatory framework
    • 8.3.7.5 Denmark cell dissociation market, 2018 - 2030 (USD Million)
  • 8.3.8 Sweden
    • 8.3.8.1 Key country dynamics
    • 8.3.8.2 Target disease prevalence
    • 8.3.8.3 Competitive scenario
    • 8.3.8.4 Regulatory framework
    • 8.3.8.5 Sweden cell dissociation market, 2018 - 2030 (USD Million)
  • 8.3.9 Norway
    • 8.3.9.1 Key country dynamics
    • 8.3.9.2 Target disease prevalence
    • 8.3.9.3 Competitive scenario
    • 8.3.9.4 Regulatory framework
    • 8.3.9.5 Norway cell dissociation market, 2018 - 2030 (USD Million)
• 8.4 Asia Pacific
  • 8.4.1 SWOT Analysis
    • 8.4.1.1 Asia Pacific cell dissociation market, 2018 - 2030 (USD Million)
  • 8.4.2 Japan
    • 8.4.2.1 Key country dynamics
    • 8.4.2.2 Target disease prevalence
    • 8.4.2.3 Competitive scenario
    • 8.4.2.4 Regulatory framework
    • 8.4.2.5 Japan cell dissociation market, 2018 - 2030 (USD Million)
  • 8.4.3 China
    • 8.4.3.1 Key country dynamics
    • 8.4.3.2 Target disease prevalence
    • 8.4.3.3 Competitive scenario
    • 8.4.3.4 Regulatory framework
    • 8.4.3.5 China cell dissociation market, 2018 - 2030 (USD Million)
  • 8.4.4 India
    • 8.4.4.1 Key country dynamics
    • 8.4.4.2 Target disease prevalence
    • 8.4.4.3 Competitive scenario
    • 8.4.4.4 Regulatory framework
    • 8.4.4.5 India cell dissociation market, 2018 - 2030 (USD Million)
  • 8.4.5 South Korea
    • 8.4.5.1 Key country dynamics
    • 8.4.5.2 Target disease prevalence
    • 8.4.5.3 Competitive scenario
    • 8.4.5.4 Regulatory framework
    • 8.4.5.5 South Korea cell dissociation market, 2018 - 2030 (USD Million)
  • 8.4.6 Australia
    • 8.3.9.1 Key country dynamics
    • 8.4.6.2 Target disease prevalence
    • 8.4.6.3 Competitive scenario
    • 8.4.6.4 Regulatory framework
    • 8.4.6.5 Australia cell dissociation market, 2018 - 2030 (USD Million)
  • 8.4.7 Thailand
    • 8.4.7.1 Key country dynamics
    • 8.4.7.2 Target disease prevalence
    • 8.4.7.3 Competitive scenario
    • 8.4.7.4 Regulatory framework
    • 8.4.7.5 Thailand cell dissociation market, 2018 - 2030 (USD Million)
• 8.5 Latin America
  • 8.5.1 SWOT Analysis
    • 8.5.1.1 Latin America cell dissociation market, 2018 - 2030 (USD Million)
  • 8.5.2 Brazil
    • 8.5.2.1 Key country dynamics
    • 8.5.2.2 Target disease prevalence
    • 8.5.2.3 Competitive scenario
    • 8.5.2.4 Regulatory framework
    • 8.5.2.5 Brazil cell dissociation market, 2018 - 2030 (USD Million)
  • 8.5.3 Mexico
    • 8.5.3.1 Key country dynamics
    • 8.5.3.2 Target disease prevalence
    • 8.5.3.3 Competitive scenario
    • 8.5.3.4 Regulatory framework
    • 8.5.3.5 Mexico cell dissociation market, 2018 - 2030 (USD Million)
  • 8.5.4 Argentina
    • 8.5.4.1 Key country dynamics
    • 8.5.4.2 Target disease prevalence
    • 8.5.4.3 Competitive scenario
    • 8.5.4.4 Regulatory framework
    • 8.5.4.5 Argentina cell dissociation market, 2018 - 2030 (USD Million)
• 8.6 MEA
  • 8.6.1 SWOT Analysis
    • 8.6.1.1 MEA cell dissociation market, 2018 - 2030 (USD Million)
  • 8.6.2 South Africa
    • 8.6.4.1 Key country dynamics
    • 8.6.2.2 Target disease prevalence
    • 8.6.2.3 Competitive scenario
    • 8.6.2.4 Regulatory framework
    • 8.6.2.5 South Africa cell dissociation market, 2018 - 2030 (USD Million)
  • 8.6.3 Saudi Arabia
    • 8.6.3.1 Key country dynamics
    • 8.6.3.2 Target disease prevalence
    • 8.6.3.3 Competitive scenario
    • 8.6.3.4 Regulatory framework
    • 8.6.3.5 Saudi Arabia cell dissociation market, 2018 - 2030 (USD Million)
  • 8.6.4 UAE
    • 8.6.4.1 Key country dynamics
    • 8.6.4.2 Target disease prevalence
    • 8.6.4.3 Competitive scenario
    • 8.6.4.4 Regulatory framework
    • 8.6.4.5 UAE cell dissociation market, 2018 - 2030 (USD Million)
  • 8.6.5 Kuwait
    • 8.6.5.1 Key country dynamics
    • 8.6.5.2 Target disease prevalence
    • 8.6.5.3 Competitive scenario
    • 8.6.5.4 Regulatory framework
    • 8.6.5.5 Kuwait cell dissociation market, 2018 - 2030 (USD Million)

Chapter 9 Competitive Landscape

• 9.1 Company Categorization
• 9.2 Company Market Positioning
• 9.3 Company Market Share Analysis, 2022
• 9.4 Company Heat Map Analysis
• 9.5 Strategy Mapping
• 9.6 Company Profiles/Listing
  • 9.6.1 Thermo Fisher Scientific Inc.
    • 9.6.1.1. Overview
    • 9.6.1.2. Financial performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.6.1.3. Product benchmarking
    • 9.6.1.4. Strategic initiatives
  • 9.6.2 Danaher Corporation
    • 9.6.2.1. Overview
    • 9.6.2.2. Financial performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.6.2.3. Product benchmarking
    • 9.6.2.4. Strategic initiatives
  • 9.6.3 STEMCELL Technologies
    • 9.6.3.1. Overview
    • 9.6.3.2. Financial performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.6.3.3. Product benchmarking
    • 9.6.3.4. Strategic initiatives
  • 9.6.4 Merck KGaA
    • 9.6.4.1. Overview
    • 9.6.4.2. Financial performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.6.4.3. Product benchmarking
    • 9.6.4.4. Strategic initiatives
  • 9.6.5 BD
    • 9.6.5.1. Overview
    • 9.6.5.2. Financial performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.6.5.3. Product benchmarking
    • 9.6.5.4. Strategic initiatives
  • 9.6.6 Sartorius AG
    • 9.6.6.1. Overview
    • 9.6.6.2. Financial performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.6.6.3. Product benchmarking
    • 9.6.6.4. Strategic initiatives
  • 9.6.7 Miltenyi Biotec
    • 9.6.7.1. Overview
    • 9.6.7.2. Financial performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.6.7.3. Product benchmarking
    • 9.6.7.4. Strategic initiatives
  • 9.6.8 PAN-Biotech
    • 9.6.8.1. Overview
    • 9.6.8.2. Financial performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.6.8.3. Product benchmarking
    • 9.6.8.4. Strategic initiatives
  • 9.6.9 HiMedia Laboratories
    • 9.6.9.1. Overview
    • 9.6.9.2. Financial performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.6.9.3. Product benchmarking
    • 9.6.9.4. Strategic initiatives
  • 9.6.10 F. Hoffmann-La Roche Ltd
    • 9.6.10.1. Overview
    • 9.6.10.2. Financial performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.6.10.3. Product benchmarking
    • 9.6.10.4. Strategic initiatives
  • 9.6.11 S2 Genomics, Inc.
    • 9.6.11.1. Overview
    • 9.6.11.2. Financial performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 9.6.11.3. Product benchmarking
    • 9.6.11.4. Strategic initiatives